SynthesisWorld journal of surgical oncology2025
TAS-102 plus bevacizumab versus TAS-102 alone for metastatic colorectal cancer: a systematic review and meta-analysis.
Synthesis in World journal of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPrevious meta-analyses have shown TAS-102's potential in metastatic colorectal cancer (mCRC). Thus, we conducted a meta-analysis to investigate the efficacy and safety of TAS-102 combined with bevacizumab versus TAS-102 monotherapy in the treatment of mCRC.
methodsA thorough search in four databases was conducted from inception to August, 2024. Overall survival (OS), progression-free survival (PFS), objective response rate (ORR) and disease control rate (DCR) were incorporated to explore the efficacy. Subgroup analysis and sensitivity analysis were then carried out to determine the sources of heterogeneity. Funnel plots and Egger's test were employed to assess publication bias.
resultsA total of 9 studies with 1,509 participants were included after screening. Compared with monotherapy, TAS-102 plus bevacizumab demonstrated encouraging outcomes both in OS (hazard ratio [HR] = 0.52, 95% confidence interval [CI] = 0.39-0.70, p < 0.001) and PFS (HR = 0.49, 95% CI = 0.39-0.62, p < 0.001). And ORR (relative ratio [RR] = 3.28, 95% CI = 1.67-6.32, p < 0.001) and DCR (RR = 1.58, 95% CI = 1.26-1.97, p < 0.001) both favored the combination group. In terms of hematological toxicity, combination group had an increased incidence of neutropenia (all grade RR = 1.51, 95% CI = 1.00-1.32; grade ≥ 3 RR = 1.38, 95% CI = 1.21-1.58) and thrombocytopenia (all grade RR = 1.44, 95% CI = 1.06-1.94).
conclusionsTAS-102 plus bevacizumab showed superior efficacy and acceptable safety over monotherapy, particularly in RAS-mutant patients, prior bevacizumab use, multiple metastases, and poorer performance status.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.